Outcomes of HSCT for autoimmune cytopenias (AIC): a Retrospective Registry Study from the Autoimmune Diseases Working Party (ADWP) and the Paediatric Working Party (PDWP) of the European Society for Blood and Marrow Transplantation (EBMT)

Study type:

Retrospective Studies

Study number:

8410034

Type of treatment:

Diseases:

Auto immune disorders

Short title:

Outcomes of HSCT for autoimmune cytopenias (AIC)

Primary objective:

To establish the safety and efficacy of first or subsequent autologous or allogeneic HSCT where the disease indication is a single or multilineage primary or secondary autoimmune cytopenia (ITP, AIHA, Evans Syndrome, AIN) treated at an EBMT centre, registered in the EBMT database.

Key inclusion criteria:

- Adult and paediatric patient treated with first autologous or allogeneic HSCT for a diagnosis of primary or secondary single or multilineage autoimmune cytopenia (ITP, AIHA, Evans syndrome, AIN). (Autoimmune disorder code 10, Haematological disorders excluding autoimmune lymphoproliferative syndrome.
- Autologous or allogeneic HSCT performed for AIC from January 1997 and December 2019

Country:

Principal investigator:

Nichola Cooper

EBMT Study coordinator:

Manuela Badoglio

Study coordinator email:

manuela.badoglio@upmc.fr